Cymbalta Finds Divergent FDA, European Standards For Fibromyalgia Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The stance of U.S and European regulators on fibromyalgia drug development is diverging, as Lilly has discovered in pursuing a fibromyalgia claim for Cymbalta (duloxetine).
You may also be interested in...
Composite Endpoints In Fibromyalgia Subject Of Dueling Citizen Petitions
In trying to convince FDA to take Cypress Biosciences and Forest Laboratories' fibromyalgia drug Savella (milnacipran) off the market, the advocacy group Public Citizen has set itself the difficult task of arguing the agency out of its established policy of accepting clinical trials with composite endpoints as proof of efficacy against the disease.
Statistics Bedeviled But Did Not Derail Cymbalta Fibromyalgia Approval
Lilly ran into one review issue with its fibromyalgia NDA for Cymbalta (duloxetine) because it did not adhere to a "well established policy" of the FDA division responsible for analgesic drugs regarding imputation of missing data, a recurring statistical issue in pain drug reviews, review documents show
Statistics Bedeviled But Did Not Derail Cymbalta Fibromyalgia Approval
Lilly ran into one review issue with its fibromyalgia NDA for Cymbalta (duloxetine) because it did not adhere to a "well established policy" of the FDA division responsible for analgesic drugs regarding imputation of missing data, a recurring statistical issue in pain drug reviews, review documents show